SEC Form 4 · accession 0001104659-18-050624
IDERA PHARMACEUTICALS, INC. · IDRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vincent Milano
Officer — President & CEO · Director
Period of report
Aug 7, 2018
Accepted (ET)
Aug 8, 2018 · 7:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000861838
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Aug 7, 2018 | P | 10,000 | $5.51 | A | 40,816 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported represents the weighted average sales price of shares purchased in multiple transactions at prices ranging from $5.49 to $5.52 per share. The reporting person hereby undertakes, upon the request of the Staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- F2Reflects the issuer's 1-for-8 reverse stock split effected on July 27, 2018.